These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9456256)

  • 1. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.
    Kuritzkes DR; Parenti D; Ward DJ; Rachlis A; Wong RJ; Mallon KP; Rich WJ; Jacobson MA
    AIDS; 1998 Jan; 12(1):65-74. PubMed ID: 9456256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer.
    Rahiala J; Perkkiö M; Riikonen P
    Med Pediatr Oncol; 1999 May; 32(5):326-30. PubMed ID: 10219332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with Filgrastim in AIDS.
    Kuritzkes DR
    J Hematother Stem Cell Res; 1999; 8 Suppl 1():S17-9. PubMed ID: 10596031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group.
    Hermans P; Rozenbaum W; Jou A; Castelli F; Borleffs J; Gray S; Ward N; Gori A; De Bona A; Ferré C; Loncà M; Lang JM; Ammassari A; Clumeck N
    AIDS; 1996 Dec; 10(14):1627-33. PubMed ID: 8970682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bacterial infections in patients with advanced HIV infection.
    Mitsuyasu R
    AIDS; 1999; 13 Suppl 2():S19-23. PubMed ID: 10596677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
    Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E
    J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
    Zhang Q; Wang Z; Yao W; Wang S; Zhang G; Chen J; Hou Q; Li S; Li H; Ye C; Sun T; Yang H; Chen Z; Wang Z; Liu X; Geng C; Li X; Zhang J; Zheng H; Shao Z
    BMC Cancer; 2024 Sep; 24(1):1143. PubMed ID: 39272058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
    Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
    Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
    McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
    J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care.
    Rapoport BL; Sussmann O; Herrera MV; Schlaeffer F; Otero JC; Pavlovsky S; Iglesias L; Stein G; Charnas R; Heitlinger E; Handschin J
    Chemotherapy; 1999; 45(6):466-76. PubMed ID: 10567777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia.
    deBoisblanc BP; Mason CM; Andresen J; Logan E; Bear MB; Johnson S; Shellito J; Summer WR; Nelson S
    Respir Med; 1997 Aug; 91(7):387-94. PubMed ID: 9327037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Filgrastim in AIDS-related neutropenia.
    Welch W; Foote M
    J Hematother Stem Cell Res; 1999; 8 Suppl 1():S9-16. PubMed ID: 10596030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.